WO2023166168 - POLYSTYRENE SULFONATE FOR USE TO TREAT NEURODEGENERATIVE DISEASES
National phase entry is expected:
Publication Number
WO/2023/166168
Publication Date
07.09.2023
International Application No.
PCT/EP2023/055419
International Filing Date
03.03.2023
Title **
[English]
POLYSTYRENE SULFONATE FOR USE TO TREAT NEURODEGENERATIVE DISEASES
[French]
SULFONATE DE POLYSTYRÈNE DESTINÉ À ÊTRE UTILISÉ POUR TRAITER DES MALADIES NEURODÉGÉNÉRATIVES
Applicants **
VIB VZW
VRIJE UNIVERSITEIT BRUSSEL
KATHOLIEKE UNIVERSITEIT LEUVEN
Inventors
TOMPA, Peter
BRATEK-SKICKI, Anna
AHMED, Junaid
Priority Data
22159883.2
03.03.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2387 | |
| EPO | Filing, Examination, Granting | 11975 | |
| Japan | Filing, Examination, Granting | 2355 | |
| South Korea | Filing, Examination, Granting | 2421 | |
| USA | Filing, Examination, Granting | 6140 |
Total:
25,278
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to the field of neurological diseases, particularly to neurodegenerative diseases caused by dipeptide repeat toxicity. The invention provides polystyrene sulfonate or a derivative thereof for use as a medicine to inhibit dipeptide repeat toxicity in a subject, to reduce axonal defects in a subject's neurons, and to treat neurological disorders related to the presence of dipeptide repeat toxicity, such as amyotrophic lateral sclerosis and frontotemporal dementia.[French]
La présente invention concerne le domaine des maladies neurologiques, en particulier des maladies neurodégénératives provoquées par une toxicité de répétition dipeptidique. L'invention concerne un sulfonate de polystyrène ou un dérivé de celui-ci destiné à être utilisé en tant que médicament pour inhiber la toxicité de répétitions dipeptidiques chez un sujet, pour réduire les défauts axonaux dans les neurones d'un sujet, et pour traiter des troubles neurologiques associés à la présence d'une toxicité de répétition dipeptidique, telle que la sclérose latérale amyotrophique et la démence frontotemporale.